Kamil Ali-Jackson net worth and biography

Kamil Ali-Jackson Biography and Net Worth

Director of Rigel Pharmaceuticals

Kamil Ali-Jackson, J.D. joined us as a director in December 2021. In January 2022, Ms. Ali-Jackson retired from her position as chief legal officer, chief compliance officer, and corporate secretary at Aclaris Therapeutics, Inc., a publicly traded clinical stage biopharmaceutical company, which she cofounded in 2012 and led the team which took the company public in 2015. In addition, Ms. Ali-Jackson co-founded and successfully transitioned several specialty pharmaceutical and biopharmaceutical companies through multimillion-dollar acquisitions by global life sciences companies. In 2011, Ms. Ali-Jackson also co-founded NeXeption, Inc. a biopharmaceutical assets management company and was legal counsel for the company and its affiliated companies until 2020. She has served as legal counsel and as a licensing business executive for a number of life science companies, including Merck & Co. Inc. and Dr. Reddy’s Laboratories Ltd. Ms. Ali-Jackson has served since February 2020 on the board of directors, audit committee, and compensation committee, and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly held clinical stage biopharmaceutical company. She has also served on several nonprofit boards and is the chair of the East Bradford Township Zoning Hearing Board, her local township zoning board. In July 2023, she was elected to the board of trustees for Princeton University. Ms. Ali-Jackson received her J.D. from Harvard Law School and Bachelor of Arts in politics from Princeton University.

What is Kamil Ali-Jackson's net worth?: The estimated net worth of Kamil Ali-Jackson is at least $387.84 thousand as of May 26th, 2026. Ali-Jackson owns 12,625 shares of Rigel Pharmaceuticals stock worth more than $387,840 as of June 9th. This net worth approximation does not reflect any other assets that Ali-Jackson may own. Learn More about Kamil Ali-Jackson's net worth.
How do I contact Kamil Ali-Jackson?: The corporate mailing address for Ali-Jackson and other Rigel Pharmaceuticals executives is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. Rigel Pharmaceuticals can also be reached via phone at (650) 624-1100 and via email at [email protected]. Learn More on Kamil Ali-Jackson's contact information.
Has Kamil Ali-Jackson been buying or selling shares of Rigel Pharmaceuticals?: During the last ninety days, Kamil Ali-Jackson has sold $72,925.00 in Rigel Pharmaceuticals stock. Most recently, Kamil Ali-Jackson sold 2,500 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $29.17, for a transaction totalling $72,925.00. Following the completion of the sale, the director now directly owns 12,625 shares of the company's stock, valued at $368,271.25. Learn More on Kamil Ali-Jackson's trading history.
Who are Rigel Pharmaceuticals' active insiders?: Rigel Pharmaceuticals' insider roster includes Kamil Ali-Jackson (Director), Walter Moos (Director), Raul Rodriguez (CEO), David Santos (EVP), and Dean Schorno (CFO). Learn More on Rigel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rigel Pharmaceuticals?: In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 6,500 shares worth more than $218,365.00. The most recent insider tranaction occured on May, 26th when Director Kamil Ali-Jackson sold 2,500 shares worth more than $72,925.00. Insiders at Rigel Pharmaceuticals own 10.5% of the company. Learn More about insider trades at Rigel Pharmaceuticals.
Information on this page was last updated on 5/26/2026.

Kamil Ali-Jackson Insider Trading History at Rigel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/26/2026	Sell	2,500	$29.17	$72,925.00	12,625

Kamil Ali-Jackson Buying and Selling Activity at Rigel Pharmaceuticals

Rigel Pharmaceuticals Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Today's Range

Now: $30.72

$30.13

$31.07

50 Day Range

MA: $29.36

$25.72

$32.49

2 Week Range

Now: $30.72

$18.14

$52.24

Volume

238,825 shs

Average Volume

381,203 shs

Market Capitalization

$568.32 million

P/E Ratio

1.64

Dividend Yield

N/A

Beta

1.2